NCT05585645View on ClinicalTrials.gov

A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)

PHASE3CompletedINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

November 23, 2022

Study Completion Date

November 23, 2022

Conditions
AnemiaChronic Kidney Disease Requiring Chronic Dialysis
Interventions
BIOLOGICAL

Stimus (NNG-DEPO)

Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe

Trial Locations (1)

Unknown

NANOGEN Pharmaceutical Biotechnology JSC, Ho Chi Minh City

Sponsors
All Listed Sponsors
collaborator

Vietstar Biomedical Research

INDUSTRY

collaborator

MEDPHASE CLINICAL RESEARCH CONSULTANT COMPANY LIMITED

UNKNOWN

collaborator

CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING COMPANY LIMITED

UNKNOWN

collaborator

MedProve Inc

UNKNOWN

lead

Nanogen Pharmaceutical Biotechnology Joint Stock Company

INDUSTRY

NCT05585645 - A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD) | Biotech Hunter | Biotech Hunter